NCT06177067
Study of Revumenib, Azacitidine, and Venetoclax in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia
StatusRecruiting
PhasePhase 1
Primary completion (estimated)
At risk: Primary completion moved at least 2 months later.
See at-risk trials from St. Jude Children's Research Hospital
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 19 versions: 17 with changes below, 2 re-verified with no change. See every version on ClinicalTrials.gov ↗
Notable Eligibility criteria expanded, about 2 words Show 5 more changesShow less
- Primary completion pushed from Oct 2026 to Jan 2027
- Study completion pushed from Apr 2027 to Feb 2029
- Secondary endpoints: details revised at 2 of 3 entries
- Study description revised
- Site details revised at 9 of 10 sites
- Minor Primary completion pushed from Jul 2026 to Oct 2026
- Site contacts updated at 1 of 10 sites
- Minor Study sites: 9 to 10v16
- Minor Study sites: 8 to 9v15
- Minor Study sites: 7 to 8v14
Show 11 earlier versionsHide 11 earlier versions
- Minor Study sites: 6 to 7v13
- Notable Eligibility criteria revised
- Primary completion date: Jan 2026 to Jul 2026
- Study completion date: Jul 2026 to Apr 2027
- Study description revised
- Minor Study sites: 5 to 6v11
- Minor Study sites: 1 to 5v10
- Notable Eligibility criteria expanded, about 18 words
- Study description expanded, about 71 words
- Minor Site contact updatedv7
- Minor Start date: Apr 21, 2024 to Apr 19, 2024v6
- Minor Start date changed from estimate of May 2024 to Apr 21, 2024v5
- Notable Trial status: Not Yet Recruiting to Recruiting
- Start date: Apr 2024 to May 2024
- Site details revised
- Minor Start date: Mar 2024 to Apr 2024v3
- Notable Start date: Jan 2024 to Mar 2024
- Eligibility criteria expanded, about 170 words
- Study description expanded, about 4 words
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
The safety and tolerability of revumenib + azacitidine + venetoclax in pediatric patients with relapsed or refractory AML or ALAL
Timeframe: 43 days from the start of therapy.
Secondary (3)
The rates of complete remission (CR)
The rates of complete remission with incomplete count recovery (CRi)
The overall survival of patients treated at the RP2D.
Arms and interventions
All Eligible ParticipantsExperimental
All eligible patients receive the following intervention: Revumenib, Venetoclax, Azacitidine, Intrathecal chemotherapy
Drugs: Revumenib, Venetoclax, Azacitidine, intrathecal (IT) chemotherapy, Cytarabine, Methotrexate
Sites
10 sites in 1 country